'Far too speculative': Amgen fights FTC's request for injunction against $28B Horizon merger

As the Federal Trade Commission tries to block Amgen’s $28 billion acquisition of Horizon Therapeutics with an injunction, Amgen has a lot to say in court filings.

The FTC’s case is “far too removed from reality and unmoored from decades of legal precedent,” Amgen’s lawyers wrote in a response to FTC’s request for a preliminary injunction. The company filed the note to a federal court in Illinois on Tuesday.